# Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females

> **NCT06893796** · PHASE1 · COMPLETED · sponsor: **Xiamen Amoytop Biotech Co., Ltd.** · enrollment: 18 (actual)

## Conditions studied

- Preeclampsia

## Interventions

- **DRUG:** Telpegfilgrastim Injection
- **DRUG:** Telpegfilgrastim Injection
- **DRUG:** Telpegfilgrastim Injection

## Key facts

- **NCT ID:** NCT06893796
- **Lead sponsor:** Xiamen Amoytop Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-26
- **Primary completion:** 2025-05-08
- **Final completion:** 2025-05-08
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06893796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06893796, "Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06893796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*